Outcomes and pathologic response of primary lung cancer treated with tyrosine kinase inhibitor/immune checkpoint inhibitor before salvage surgery.

IF 1.7 4区医学 Q2 SURGERY

Surgery Today Pub Date : 2024-10-01 Epub Date: 2024-03-14 DOI:10.1007/s00595-024-02811-3

Masaru Takenaka, Fumihiro Tanaka, Kenta Kajiyama, Takehiko Manabe, Katsuma Yoshimatsu, Masataka Mori, Masatoshi Kanayama, Akihiro Taira, Taiji Kuwata, Aya Nawata, Koji Kuroda

{"title":"Outcomes and pathologic response of primary lung cancer treated with tyrosine kinase inhibitor/immune checkpoint inhibitor before salvage surgery.","authors":"Masaru Takenaka, Fumihiro Tanaka, Kenta Kajiyama, Takehiko Manabe, Katsuma Yoshimatsu, Masataka Mori, Masatoshi Kanayama, Akihiro Taira, Taiji Kuwata, Aya Nawata, Koji Kuroda","doi":"10.1007/s00595-024-02811-3","DOIUrl":null,"url":null,"abstract":"Purpose: Advances in primary lung cancer drug therapy have extended patients' survival, including patients with stage IV disease. This study assessed the safety and effectiveness of salvage surgery following tyrosine kinase inhibitor (TKI) or immune checkpoint inhibitor (ICI) therapy in primary lung cancer.Methods: A retrospective chart review was conducted of 2050 primary lung cancer surgeries performed at our institution between 2012 and 2022. The study included patients who underwent salvage surgery for unresectable lesions that became resectable or localized residual lesions after treatment. We investigated patients' clinicopathological characteristics, therapeutic responses, and survival outcomes.Results: We identified eight cases of salvage surgery after TKI treatment and eight cases after ICI treatment. Five patients experienced early recurrence after surgery; however, the long-term outcome in the post-TKI group was favorable, with a median overall survival (OS) of 66 (range: 28-80) months. Postoperative recurrence was confined to local lymph node recurrence in one patient in the post-ICI group. Despite the relatively short observation period, the long-term prognosis remained promising, with a median OS of 18.7 (range: 9.7-55.8) months.Conclusions: Salvage surgery after TKI or ICI treatment can be safely performed, and the OS may be favorable.","PeriodicalId":22163,"journal":{"name":"Surgery Today","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Surgery Today","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00595-024-02811-3","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Advances in primary lung cancer drug therapy have extended patients' survival, including patients with stage IV disease. This study assessed the safety and effectiveness of salvage surgery following tyrosine kinase inhibitor (TKI) or immune checkpoint inhibitor (ICI) therapy in primary lung cancer.

Methods: A retrospective chart review was conducted of 2050 primary lung cancer surgeries performed at our institution between 2012 and 2022. The study included patients who underwent salvage surgery for unresectable lesions that became resectable or localized residual lesions after treatment. We investigated patients' clinicopathological characteristics, therapeutic responses, and survival outcomes.

Results: We identified eight cases of salvage surgery after TKI treatment and eight cases after ICI treatment. Five patients experienced early recurrence after surgery; however, the long-term outcome in the post-TKI group was favorable, with a median overall survival (OS) of 66 (range: 28-80) months. Postoperative recurrence was confined to local lymph node recurrence in one patient in the post-ICI group. Despite the relatively short observation period, the long-term prognosis remained promising, with a median OS of 18.7 (range: 9.7-55.8) months.

Conclusions: Salvage surgery after TKI or ICI treatment can be safely performed, and the OS may be favorable.

查看原文本刊更多论文

抢救性手术前使用酪氨酸激酶抑制剂/免疫检查点抑制剂治疗原发性肺癌的疗效和病理反应。

目的：原发性肺癌药物治疗的进步延长了患者的生存期，包括IV期患者。本研究评估了原发性肺癌患者在接受酪氨酸激酶抑制剂（TKI）或免疫检查点抑制剂（ICI）治疗后进行挽救手术的安全性和有效性：我们对本机构在2012年至2022年期间进行的2050例原发性肺癌手术进行了回顾性病历审查。研究对象包括因无法切除的病灶而接受挽救手术的患者，这些病灶在治疗后成为可切除病灶或局部残留病灶。我们调查了患者的临床病理特征、治疗反应和生存结果：我们发现了 8 例 TKI 治疗后的挽救性手术和 8 例 ICI 治疗后的挽救性手术。5例患者术后出现早期复发；然而，TKI治疗后组的长期预后良好，中位总生存期（OS）为66个月（范围：28-80）。术后复发仅限于ICI术后组的一名患者局部淋巴结复发。尽管观察期相对较短，但长期预后仍然良好，中位OS为18.7个月（范围：9.7-55.8）：结论：TKI或ICI治疗后的抢救性手术可以安全进行，且OS可能良好。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Surgery Today 医学-外科

CiteScore

4.90

自引率

4.00%

发文量

208

审稿时长

1 months

期刊介绍： Surgery Today is the official journal of the Japan Surgical Society. The main purpose of the journal is to provide a place for the publication of high-quality papers documenting recent advances and new developments in all fields of surgery, both clinical and experimental. The journal welcomes original papers, review articles, and short communications, as well as short technical reports("How to do it"). The "How to do it" section will includes short articles on methods or techniques recommended for practical surgery. Papers submitted to the journal are reviewed by an international editorial board. Field of interest: All fields of surgery.